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SUMMARY
Interferon-induced transmembrane proteins (IFITMs)
restrict the entry of diverse enveloped viruses through
incompletely understood mechanisms. While IFITMs
are reported to inhibit HIV-1, their in vivo relevance
is unclear. We show that IFITM sensitivity of HIV-1
strains is determined by the co-receptor usage of
the viral envelope glycoproteins as well as IFITM sub-
cellular localization within the target cell. Importantly,
we find that transmitted founder HIV-1, which estab-
lishes de novo infections, is uniquely resistant to the
antiviral activity of IFITMs. However, viral sensitivity
to IFITMs, particularly IFITM2 and IFITM3, increases
over the first 6monthsof infection, primarily asa result
of neutralizing antibody escape mutations. Addition-
ally, the ability to evade IFITM restriction contributes
to the different interferon sensitivities of transmitted
founder and chronic viruses. Together, these data
indicate that IFITMs constitute an important barrier
to HIV-1 transmission and that escape from adaptive
immune responses exposes the virus to antiviral
restriction.
INTRODUCTION
Robust systemic type 1 interferon (IFN-1) responses are among
the earliest host innate immune defenses during acute SIV
and HIV-1 infection (Abel et al., 2005; Stacey et al., 2009). In pri-
mary CD4+ T cells andmacrophages, expression of IFN-induced
genes (ISGs) restricts viral replication (Goujon and Malim,
2010), and treatment of rhesus macaques with IFN-1 increased
the number of intrarectal challenges required to achieve sys-
temic SIVmac infection and reduced the number of transmitted
founder (TF) viruses (Sandler et al., 2014). While the virus
encodes countermeasures against important ISGs, such as
APOBEC3G and tetherin (BST2/CD317), other ISGs appear to
restrict viral replication in cell culture with no obvious viral
evasion mechanism, and thus their physiological relevance in
the transmission and pathogenesis of HIV/AIDS remains unclear
(Doyle et al., 2015).
One such family of ISGs, the IFN-induced transmembrane
proteins 1–3 (IFITMs 1–3), has broad activity against diverse
enveloped viruses, particularly influenza A virus (IAV) (reviewed
in Smith et al., 2014). IFITMs are small (125–135 amino acids)
membrane-spanning proteins whose topology is still a matter
of debate. In the most favored conformation (Bailey et al.,
2013; Ling et al., 2016; Weston et al., 2014), the N-terminal
region is cytosolic, followed by a semi-transmembrane (TM)
domain that remerges from the cytosolic face, which, after an
intracellular loop containing essential palmitoylation sites (Yount
et al., 2010), turns into a canonical TM helix that exposes the
C terminus on the extracellular side. In humans IFITMs 2 and
3 are highly homologous with only ten amino acid differences
between them. Both have longer N-terminal tails than IFITM1,
in which an overlapping PPXY and YxxF site interacts with
NEDD4 family ubiquitin ligases (Chesarino et al., 2015) and the
clathrin adaptor AP-2, respectively (Jia et al., 2014). IFITM2
and 3 localize predominantly to different endosomal compart-
ments at steady state (Weston et al., 2014). This is determined
in part by the AP-2 binding, implying that they traffic via the
cell surface (Jia et al., 2012, 2014; Weston et al., 2014). By
contrast, IFITM1 lacks an obvious trafficking sequence and is
primarily expressed at the plasma membrane. A human poly-
morphism defined by a SNP, rs12252-C, has been proposed
to lead to an alternatively spliced variant of IFITM3 that truncates
the N terminus after the YxxFmotif, thereby reducing its antiviral
activity against IAV and accounting for enhancedmorbidity in the
recent H1N1 swine flu pandemic (Everitt et al., 2012).
IFITM3 has been shown to restrict IAV entry at the stage of
fusion in the endosome (Amini-Bavil-Olyaee et al., 2013; Desai
et al., 2014; Li et al., 2013). Although the mechanism is not well
understood, this restriction may be due to the effects of IFITM3
on membrane fluidity and/or cholesterol trafficking or biosyn-
thesis (Amini-Bavil-Olyaee et al., 2013; Desai et al., 2014;
Lin et al., 2013). In contrast to the effects of IFITMs on pH-depen-
dent virus entry, their ability to restrict HIV-1 is less clear cut.
The antiviral effects of IFITMs so far observed have been vari-
ously ascribed to virion incorporation during assembly (Compton
Cell Host & Microbe 20, 1–14, October 12, 2016 ª 2016 The Author(s). Published by Elsevier Inc. 1
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Foster et al., Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction, Cell Host & Microbe (2016),
http://dx.doi.org/10.1016/j.chom.2016.08.006
et al., 2014; Tartour et al., 2014) or inhibition of processing of
the HIV-1 envelope glycoprotein (Yu et al., 2015), with little
consensus as to their mechanism and sites of action. It is, how-
ever, difficult to rationalize these mechanisms with the clear
inhibitory effects in the target cell for all other enveloped viruses
thus far examined. Moreover, the effect that IFITMs might have
on HIV-1 tropism has not been studied.
HIV-1 enters cells through engagement of its envelope glyco-
protein with CD4 and a chemokine receptor co-receptor, CCR5
(R5) or CXCR4 (X4) (Wilen et al., 2012). CD4 interaction induces
conformational changes in the surface (SU) subunit of Env,
gp120, which exposes the co-receptor-binding site. Upon co-re-
ceptor engagement, further conformational changes in the TM
gp41 subunit activate its membrane fusion capacity. R5 usage
is essential for viral transmission, with a switch to X4 observed
in 50% of patients with subtype B infections but less common
in other clades. Furthermore, while R5 and X4 viruses are
both capable of infecting CD4+ T cells, tropism of R5 strains
for macrophages is more complex. Most R5 viruses, including
TF viruses, cannot efficiently infect macrophages. Macrophage
tropism is almost exclusively R5 dependent, but also requires
adaptation in gp120 to use very low levels of CD4 (Duenas-
Decamp et al., 2010). It is also not clear why, despite constitutive
expression of CXCR4 on macrophages, most X4 viruses cannot
infect them (Simmons et al., 1998). Finally, there are examples of
HIV-1 and SIV restriction in certain cell types that appear depen-
dent on the route of viral entry (Pineda et al., 2007; Schmitz et al.,
2004). Although generally thought of as a virus that fuses at the
cell surface, some HIV-1 strains fuse in endosomes in some
cell types (Miyauchi et al., 2009).
Given these observations, we set out to examine whether
IFITMs could restrict HIV-1 strains with differing receptor tro-
pisms. In doing so, we found that IFITM restriction of HIV-1 is
modulated by co-receptor usage and subcellular localization of
the IFITM, suggesting different entry pathways depending on
Env/receptor interactions. Furthermore, we found that TF viruses
are uniquely IFITM resistant, a property that is lost during chronic
infection, in part due to escape mutations acquired in response
to autologous neutralizing responses.
RESULTS
IFITMs Differentially Restrict HIV-1 Isolates Depending
on Co-receptor Tropism
To examine the role of IFITMs in restricting HIV-1 replication,
we constructed U87 neuroblastoma cells (which do not ex-
press detectable IFITMs without IFN induction) encoding CD4
together with one of the two major co-receptors, CXCR4 or
CCR5, to express IFITM1, IFITM2, and IFITM3, respectively (Fig-
ure S1A, available online). Importantly, the IFITM expression
levels in these engineered cell lines were of a similar magnitude
compared to those of monocyte-derived macrophages and
CD4+ T cells in the presence and absence of IFN-1 (Figure S1B).
IFITM expression did not alter CD4 or co-receptor expression in
these cells (Figure S1C).We then analyzed the infectivity of HIV-1
Env pseudotypes as well as replication-competent molecular
clones in these cells (Figures 1A, 1B, S1D, and S1E). Testing
both single-round infectivity and cumulative 96-hr replication,
we found that X4-using viruses displayed a significantly greater
sensitivity to IFITMs 2 and 3 than did the R5 viruses (Figures 1,
S1D, and S1E). In contrast, most R5 viruses tested were more
sensitive to IFITM1 than X4 viruses. However, this difference
achieved statistical significance only after the removal of two
outlier R5 strains (CH105 and THRO), the reasons for which
will be addressed below. Intriguingly the R5/X4 isolate 89.6
displayed distinct restriction patterns dependent on whether
it entered target cells using CXCR4 or CCR5 (Figures 1A, 1B,
and S1D). In the former case it had a singular sensitivity to
IFITM2, whereas in the latter case this was relieved in favor of
greater IFITM1 sensitivity.
To formally demonstrate that co-receptor usage influences
IFITM sensitivity, we pseudotyped lentiviral vectors with enve-
lopes from prototypic R5 (YU2) and X4 (HxB2) using strains in
which the determinant of co-receptor use, the V3 loop (Sullivan
et al., 1998), had been exchanged. This resulted in exchange
of the restriction phenotype between the two envelope pro-
teins (Figure 1C). This indicates that a given IFITM’s antiviral
activity is modulated by the receptor requirements of the infect-
ing virus. Importantly one-round infectivities and multiple-round
replication results correlated, and we saw no differential effects
of IFITM expression on envelope precursor processing to
gp120 (Figure S1F), suggesting IFITM restriction only affected
Env-mediated cell entry, in contrast to a previous report (Yu
et al., 2015).
Subcellular Localization of IFITMs Correlates with
Differential HIV-1 Restriction
The differential restriction of X4 and R5 tropic HIV-1 prompted us
to examine whether IFITM localization underlies these pheno-
types. Available antibodies cannot distinguish between human
IFITMs by immunofluorescence, so we used C-terminally HA-
tagged proteins stably expressed in U87 cells. Unlike IFITM1,
which is predominantly found at the cell surface, IFITMs 2 and
3 localize to endosomal compartments (Figure 2A) (Weston
et al., 2014). Endosomal localization of IFITM2 and 3 depends
on a YXXF-binding site for the clathrin adaptor AP-2. When the
Y residue is mutated to a phenylalanine, both proteins readily
localize to the cell surface (Figure 2B). Using the V3 loop-swap
viral pseudotypes, we found that we could reverse the restriction
patterns observed above: R5 tropism was sensitive to surface-
expressed IFITM2 and 3, whereas X4 tropic restriction was
relieved (Figure 2C). Similarly, the restriction of replication of
the dual tropic 89.6 virus by IFITM2 in a CXCR4 context was
completely abolished upon its relocalization to the cell surface
(Figure 2D). We could mirror these findings by reversing 89.6’s
IFITM2 sensitivity by knocking down AP-2 in CXCR4-expressing
cells (Figure 2E). We also could show that the V3 swap variants
that use X4 could be rescued from IFITM2 and 3 restriction by
the inhibition of endocytosis with the dynamin inhibitor dynasore
and the clathrin inhibitor Pitstop2 (Figure 2F). The differential re-
striction patterns depending on IFITM localization suggest that
X4 HIV-1 isolates may fuse preferentially in different subcellular
compartments compared to R5 viruses.
Recent publications suggest that IFITM incorporation into
HIV-1 particles affects their infectivity and contributes to viral
restriction (Compton et al., 2014; Tartour et al., 2014). We
examined incorporation of IFITMs and mutants into CD45-
depleted pelleted 89.6 virions (Coren et al., 2008). Despite the
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differential restriction of viral replication by endosomal IFITMs
and mutants, we found no evidence that this correlated with
virion incorporation, which remained constant (Figure S2B).
Thus, restriction of HIV-1 entry depends on the localization of
the IFITM in the target cell, and it suggests that viral sensitivity
is the result of co-receptor-mediated targeting of the entry pro-
cess to subcellular compartments where IFITMs are differen-
tially expressed.
Figure 1. Sensitivity of HIV-1 to IFITM Inhibition Varies with Co-receptor Usage
(A) GFP-encoding HIV-1 vectors pseudotyped with the indicated envelope glycoproteins were used to infect U87/CD4/CCR5 or U87/CD4/CXCR4 cells stably
expressing IFITMs 1, 2, or 3 or empty vector (control). The percentage of GFP+ cells compared to control was determined by flow cytometry, and results shown
represent a mean of independent experiments. Statistics were performed using an unpaired two-tailed t test (***p < 0.001; **p < 0.01; *p < 0.05; ns, p > 0.05).
(B) Cumulative viral replication at 96 hr in the presence of IFITMs differs for CXCR4-using or CCR5-using HIV-1 virus isolates. U87/CD4/CCR5 or U87/CD4/
CXCR4 cells were infected at an MOI of 0.05, and replication was monitored by viral output on HeLa-TZMbl indicator cells (see also Figures S1D and S1E). Each
virus point represents a mean of three independent experiments. Inset red dashed boxes: CCR5-using CH105 and RHPA are founder virus isolates that
are resistant to IFITM inhibition. Removal of these outliers reveals data significance between CXCR4 and CCR5 users in the presence of IFITM1 (***p < 0.001;
**p < 0.01; *p < 0.05; ns, p > 0.05, based on an unpaired two-tailed t test).
(C) Pseudotyped HIV vectors were produced with wild-type YU2 and Hxb2 envelopes or V3 loop swap variants and analyzed as in (A).
All error bars represent ± SEM (n = 3). See also Figure S1.
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TF HIV-1 Strains Are Resistant to IFITMs
In the analysis shown in Figure 1, several viruses were almost
completely resistant to IFITM restriction. In all cases these were
TF viruses, which represent viruses that establish de novo infec-
tion following HIV-1 transmission (Salazar-Gonzalez et al., 2009).
Using a panel of TF molecular clones (Figure 3A) as well as indi-
vidual TFEnvs (Figure S3A), we found that in U87CD4/CCR5cells
the great majority of these viruses were resistant to all three
human IFITMs, with relocalization to the plasma membrane of
IFITMs 2 and 3 having only minor effects (Figure S3B). For six
TF viruses, matched 6-month consensus molecular clones from
the same individual were available, all of which previously had
been shown to be particularly sensitive to the antiviral effects of
IFN-1 (Fenton-Mayet al., 2013). In all of thesecases,weobserved
a striking increase in their sensitivities to IFITM2 and IFITM3 (Fig-
ures 3A and 3B), whichwas relieved upon IFITM2/3 relocalization
to the plasma membrane (Figure S3B). All the TF/6-month pairs
were singularly R5 tropic except for CH077, where the founder
was able to use CXCR4 at a lower efficiency (not shown). The
IFITM phenotypes could be transferred to lentiviral vectors pseu-
dotyped with the respective envelope glycoproteins, indicating
that amino acid changes in Env during the transition from acute
to chronic infection were associated with IFITM-mediated re-
striction (Figure 3C). Furthermore, a panel of Envs derived from
a clade C-infected patient, generated at the time of transmission
through 39 months post-infection (Doria-Rose et al., 2014), ex-
hibited progressive sensitization to IFITMs 2 and 3, with clear
phenotypes appearing by 8 months (Figure 3D).
While there were no common amino acid changes in Env that
were shared between the various TF/6-month pairs, most differ-
ences mapped to the external surfaces of the trimers and the
variable loops (Figure S3C; Table S1). This raised the possibility
that adaptive changes in Env that accrued in response to host
immune responses during the course of the infection might
explain the increased sensitivities to IFITMs 2 and 3. In three
TF/6-month pairs, amino acid positions in the 6-month enve-
lope previously have been identified to mediate evasion of early
autologous neutralizing antibody (NAb) responses (Figure 4A;
Table S2) (Bar et al., 2012). Importantly, experimental reversion
of these amino acids in the 6-monthmolecular clones completely
restored the IFITM resistance (Figure 4B).
The resistance of the 6-month viruses to surface-retained
IFITM2 or 3 (Figure S3B) prompted us to seek evidence that
alterations in viral entry modulated by receptor engagement
could explain the increased IFITM sensitivities of the 6-month
variants. First we found that the sensitivity of the 6-month viruses
to IFITM2 or 3 could be abolished by AP-2 depletion (Figures 5A
and S4A) or treatment of the cells with endocytosis inhibitors
(Figures 5B and S4B). Since all the viruses were R5 tropic,
we then compared TF/6-month pairs in the presence of limiting
surface CD4 density with a blocking antibody. Intriguingly, for
CH077, CH058, and CH470 TF clones and the corresponding
NAb revertants, an IFITM2/3 restriction phenotype similar to
the 6-month variant could be induced by limiting CD4 levels
(Figure 5C). Conversely, the 6-month variants themselves main-
tained their restriction profile irrespective of entry inhibition by
CD4 neutralization. Together these data argue that the primary
engagement with CD4 at the plasmamembrane is a major deter-
minant of IFITM resistance in the TF viruses and the accrual of
amino acid variations under immune pressure impacts on the
cellular route of entry, leading to IFITM2 and 3 restriction.
IFITM Depletion in CD4+ T Cells Rescues 6-Month Viral
Isolates from IFN-1
Amajor challenge with ISGs that restrict HIV-1 in cultured cells is
demonstrating that they have relevance in primary targets. The
reported acquisition of IFN-1 sensitivity in the 6-month viruses
(Fenton-May et al., 2013) prompted us to determine whether
IFITMs were contributing factors. We first determined the local-
ization of IFITMs in Jurkat T cells transduced with the same HA-
tagged constructs used for microscopy in our U87 cells (Figures
S5A and S5B). As in the U87 cells, IFITM1was almost exclusively
at the plasma membrane. Aside from some minor surface label-
ing, IFITM3 was found in intracellular endosomes. IFITM2 could
be detected at the plasma membrane, but, upon permeabliza-
tion, 3- to 4-fold more was stained in flow cytometry, indicating
that the majority localization was again intracellular.
To assess the contribution of IFITMs to HIV-1 IFN-1 sensitivity,
lentiviral vectors pseudotyped with TF or 6-month envs were
used to transduce U87/CD4/CCR5 after pretreatment overnight
with 500 U IFN-1. The 6-month envs displayed a greater reduc-
tion in one-round infectivity after IFN-1 treatment, indicating that
Figure 2. A Conserved N-Terminal Tyrosine Residue Is Crucial for IFITM Localization and Affects the IFITM Inhibition Phenotypes of HIV-1
(A) Schematic representation of human IFITM1, IFITM2, and IFITM3 proteins, indicating the localization of a conserved tyrosine at the N terminus of IFITMs 2 (Y19)
and 3 (Y20). The localization of the IFITM proteins was assessed using U87 cells transduced with the indicated HA-tagged IFITM. Cells were stained with anti-HA
(green) antibody and co-stained with early or late endosomal markers anti-EEA1 (red) or anti-CD63 (red).
(B) Top: localization of HA-tagged IFITM2-Y19F or IFITM3-Y20F in U87 cells as in (A). Bottom: localization of HA-tagged IFITM2 or IFITM3 in U87, with or without
small interfering RNA (siRNA)-mediated knockdown of AP-2, is shown.
(C) As in Figure 1C, pseudotyped viruses were produced with wild-type YU2 and Hxb2 envelopes as well as V3 loop swaps. The percentage of infected cells,
in the presence of either wild-type or mutant IFITM protein, was determined by flow cytometry (***p < 0.001; **p < 0.01; *p < 0.05; ns, p > 0.05, unpaired two-tailed
t test).
(D) U87/CD4/CXCR4 cells expressing IFITM2 or IFITM2-Y19F were infected with 89.6 env-pseudotyped HIV-1 vector (left) or with full-length HIV-1 89.6 at anMOI
of 0.05 (right), and they were analyzed as in Figures 1A and S1D, respectively (***p < 0.001, unpaired two-tailed t test).
(E) The effect of AP2 siRNA knockdown in U87/CD4/CXCR4 on the inhibition of 89.6 proviral replication. Cells were treated with control or AP2-specific
SMARTpool siRNA and infected with 89.6. Then 48 hr post-infection, supernatants were assessed for viral production, and lysates were examined for the
expression of AP2 and loading control HSP90 by western blot. Statistical significance was determined by using an unpaired two-tailed t test (***p < 0.001; **p <
0.01; *p < 0.05; ns, p > 0.05).
(F) Effect of endocytosis inhibitors dynasore and Pitstop2 on IFITM restriction of pseudotyped virus entry. U87/CD4/CoR cells expressing the indicated IFITM
were exposed to dynasore (80 mM), Pitstop 2 (30 mM), or DMSO as a control, for 30 min prior to infection with the indicated env-pseudotyped viruses. The
percentage of GFP+ cells was determined by flow cytometry (***p < 0.001; **p < 0.01; *p < 0.05; ns, p > 0.05, unpaired two-tailed test).
All error bars represent ± SEM (n = 3). See also Figure S2.
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the envelopes contained an IFN sensitivity determinant (Fig-
ure 6A). We next employed CRISPR-Cas9 lentiviral vectors tar-
geting individual IFITMs or an irrelevant control (luciferase). While
each guide effectively knocked out the specific IFITM targeted,
the degree of homology between them and, presumably, their
chromosomal positioning and proximity resulted in effective
deletion of IFITM2 by IFITM3 guides and vice versa, as well as
reduced expression of both IFITMs 2 and 3 by the IFITM1 guide
(Figure 6B). Using a TF/6-month pair, CH077, that only displayed
IFITM2 and 3 sensitivity, we found that, in U87/CD4/CCR5 cells,
only the 6-month variant displayed IFN-1 sensitivity (Figure 6C).
Moreover, treatment with the IFITM CRISPR guides relieved this
IFN-induced restriction, with no effect on the TF virus. This indi-
cates that expression of IFITMs contributes to the different IFN
sensitivities of TF and 6-month virus.
We next moved into primary human CD4+ T cells using lentivir-
ally delivered small hairpin RNAs (shRNAs). Again, due to their
high degree of homology, effective shRNAs displayed a degree
of cross-knockdown, particularly between IFITMs 2 and 3 (Fig-
ure 6D). However, using cells from three independent donors,
we examined cumulative replication of CH040 and CH470 after
5 days in the presence or absence of 500 U/mL universal
IFN-1. The TF variants of both viruses displayed a weak sensi-
tivity to IFN-1 treatment, with little or no effect of any of the
shRNAs. In contrast, replication of the 6-month variants was
markedly reduced by IFN (Figure 6E). In the case of CH040,
this IFN sensitivity was rescued by shRNAs targeting IFITMs 2
or 3, but not IFITM1, consistent with the replication of this virus
in our engineered cells (Figure 3). For CH470, knockdown of
IFITM1 also contributed to the rescue. Importantly, for CH040,
the NAb revertant virus behaved like the TF virus, which is IFN
resistant and unresponsive to IFITM knockdown (Figure 6E).
Taken together, these data demonstrate that IFITMs are relevant
HIV-1 antiviral factors in primary human cells and substantially
contribute to the IFN-1 sensitivity of chronic phase viruses in a
manner dependent on escape mutations of the envelope to
host immune responses. These data also suggest that IFITM
resistance in TF viruses is an important attribute in vivo.
DISCUSSION
We have re-examined the roles of IFITMs in the restriction of
HIV-1 entry, and we present evidence that is consistent with
them having a role in the innate immune response against the
virus during the earliest stages of acute HIV-1 infection. Spe-
cifically, we found that TF HIV-1 is IFITM resistant but that the
virus acquires sensitivity progressively over time. This increased
IFITM sensitivity correlates with the acquisition of Env mutations
previously shown to mediate escape from early autologous
neutralization (Bar et al., 2012), and, thus, it explains at least
some of the IFN-1 sensitivity previously shown to emerge during
chronic infection (Fenton-May et al., 2013). Additionally, we
document that the patterns of IFITM sensitivity of chronic and
lab-adapted isolates of HIV-1 are determined by their co-recep-
tor use and the subcellular localization of the IFITM itself. These
data strongly suggest that co-receptor usage affects the route of
cellular entry such that the virus fuses in different subcellular
compartments.
The mechanism of action of IFITMs remains poorly under-
stood. For most pH-dependent viruses, IFITM3 in particular in-
duces the accumulation of virions in late endosomes because
of a lack of proper envelope-mediated fusion. This has been
proposed to be as a result of IFITM3 interaction with VAMP-
associated protein (VAPA) leading to the dysregulation of sterol
trafficking (Amini-Bavil-Olyaee et al., 2013), although this has
yet to be confirmed by others. In keeping with the notion of
membrane modification, the antifungal drug amphotericin B,
which modulates cholesterol synthesis, inhibits IFITM3 restric-
tion of IAV (Lin et al., 2013). By contrast, the effects of IFITMs
on HIV-1 have been less well defined. While all have been shown
to have effects on viral infectivity (Lu et al., 2011), the small differ-
ences observed in one-round infections have led to speculations
of altered envelope processing/incorporation in the producer
cells (Yu et al., 2015) or viral membrane incorporation (Compton
et al., 2014; Tartour et al., 2014). In our cell lines expressing phys-
iologically relevant IFITM levels, we saw no envelope-processing
defects, and, despite the IFITM incorporation into nascent vi-
rions, the infectivity phenotypes we observed correlate only
with the expression/localization of the IFITM in the target cell.
The dependence of viral restriction on IFITM localization
has important implications for HIV-1 entry and tropism. The
sequential engagement of CD4 and co-receptor leads to com-
plex conformational changes in Env that activate membrane
fusion (Wilen et al., 2012). Since these events are pH indepen-
dent, it is widely assumed that fusion takes place at the plasma
membrane. However, it has been proposed that HIV-1 enters by
dynamin-dependent endocytic processes (Miyauchi et al.,
2009). This is countered by observations that, while such entry
may be observable, the endocytosis is not necessary for produc-
tive infection (Herold et al., 2014; Pelchen-Matthews et al., 1995).
The restriction of X4 and some R5 viruses by IFITM2 or IFITM3,
which is dependent on the AP-2-binding site, suggests that the
Figure 3. TF Virus Replication Is Resistant to IFITMs, with Sensitivity Arising at 6 Months
(A) U87/CD4/CCR5 IFITM-expressing cells were infected with the indicated TF molecular clones or cognate 6-month variant at an MOI of 0.05, and infection was
assayed with supernatants harvested every 24 hr for 7 days. Viral production was measured on HeLa-TZMbl indicator cells. Data represent a summary of three
independent experiments.
(B) Comparison of the relative cumulative replication in 3A at the 96-hr time point was analyzed by a paired Mann-Whitney test (***p < 0.001; **p < 0.01; *p < 0.05;
ns, p > 0.05).
(C) HIV-1 vectors pseudotyped with envelopes of CH058, CH077, and CH470 TF and 6-month viruses were used to infect U87/CD4/CCR5 IFITM cells, analyzed
as in Figure 1A. The percentage of infected cells was determined by flow cytometry, and results shown represent three independent infection experiments (***p <
0.001; **p < 0.01; *p < 0.05; ns, p > 0.05, unpaired two-tailed test).
(D) Sequential envelopes derived from the CAP256 patient (CAP256.1MO.C7J [1 month], CAP256.3MO.C9 [3 months], CAP256.8MO.31 [8 months],
CAP256.12MO.1 [12 months], CAP256.14MO.5b [14 months], CAP256.21MO.A1 [21 months], and CAP256.39MO.10 [39 months]) were used to produce
pseudotyped HIV-1 vectors and infect of U87/CD4/CCR5 IFITM cells (**p < 0.01; *p < 0.05; ns, p > 0.05, unpaired two-tailed test).
All error bars represent ± SEM (n = 3). See also Figure S3 and Table S1.
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subcellular location of viral entry among different HIV-1 strains
is variable. These observations do not necessarily mean that
all IFITM2/3-sensitive viruses fuse in endosomes. Both IFITMs
2 and 3 accumulate in endosomes after AP-2-mediated internal-
ization from the plasma membrane, and so there will always
be a pool at the cell surface. However, they will be associ-
ated with endocytic domains such as clathrin-coated pits; by
contrast, the tyrosine-mutated IFITM2/3 will not be. Therefore,
the pattern of IFITM restriction implies that different viruses enter
cells at spatially distinct localizations. That this is dependent
on X4 usage or CD4 density (in the case of the 6-month viruses)
suggests that receptor engagement and/or trafficking is a prime
determinant of entry site. It is known that CCR5 and CXCR4
traffic differently when engaged in ligand-dependent signaling
Figure 4. Reversion of Neutralization Escape Mutants in 6-Month Viruses Restores IFITM Resistance
(A) The gp120:gp41 trimer structures show the NAb escape mutations of CH040, CH058, and CH077 in red. Gp120, green; gp41, blue. Images were drawn using
PDB: 5ACO in Pymol.
(B) U87/CD4/CCR5 IFITM cells were infected with the indicated 6-month chronic viruses or those containing NAb escape reversion mutations at an MOI of 0.05.
Cumulative replication over a period of 96 hr was assayed for viral production on HeLa-TZMbl indicator cells as in Figures 3A and 3B.
Statistics were performed using a paired Mann-Whitney test (***p < 0.001; **p < 0.01; *p < 0.05; ns, p > 0.05). See also Table S2.
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Figure 5. Effect of Endocytosis Inhibitors and Surface CD4 Levels on IFITM Restriction of TF and 6-Month Viral Entry
(A) U87/CD4/CCR5 IFITM cells were treated with control or AP-2-specific siRNAs for 48 hr and then infected with the indicated HIV-1-pseudotyped vector. GFP+
cells were analyzed as in Figure 1A (***p < 0.001; **p < 0.01; *p < 0.05; ns, p > 0.05, unpaired two-tailed test). Knockdownwas assessed bywestern blot for AP-2m.
(B) As in (A) but the cells were pretreated with DMSO, dynasore, or Pitstop2.
(legend continued on next page)
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(Signoret et al., 1998), and there is much suggestive evidence
that co-receptor engagement by incoming HIV-1 also induces
signaling (Wu and Yoder, 2009). Interestingly, the entry of the R5
user YU2 could be rescued from IFITM1 by endocytic blockade,
indicating that modulation of receptor trafficking in the plane
of the plasma membrane may affect viral entry site at the cell
surface. Our data therefore suggest that the patterns of IFITM
restriction can be used to dissect the role of endocytic trafficking
inHIV-1entry,whichhas important implications forunderstanding
cell tropism and co-receptor switching.
Unlike the restriction factors APOBEC3G, tetherin, and
SAMHD1, which are directly counteracted by lentiviral-encoded
accessory proteins, there is no direct evidence for the relevance
of any other specific ISG-mediated restriction in vivo, despite
abundant evidence that many can target specific stages of the
replication cycle in cultured systems (Doyle et al., 2015). How-
ever, the acquisition of IFN-1 sensitivity by chronic viruses is
highly suggestive that some must do so at physiological expres-
sion levels (Fenton-May et al., 2013; Parrish et al., 2013). ISGs
that are directly antiviral often target viral structures (the cell-
derived membrane) or processes (reverse transcription), which
cannot simply be mutated (Doyle et al., 2015). As such, the entry
pathway of the virus is a perfect target for the host.
The most striking observation in our study is that, while we see
varying IFITM sensitivities for lab-adapted and chronic strains of
HIV-1, the TF virus envelope proteins are almost uniformly resis-
tant to their activities. The acquisition of sensitivity to IFITMs over
the ensuing months strongly suggests that their avoidance is
a requirement for HIV-1 to be successfully transmitted. Themap-
ping to residues exposed on the outer faces of the envelope tri-
mers and the timing of the acquisition itself suggest that immune
escape mutations might be driving IFITM sensitivity. Broadly
NAbs are generally observed only after several years of infec-
tion (Burton and Mascola, 2015). However, complement-fixing
anti-Env antibodies are detectable coincident with the onset
of T cell immunity (Aasa-Chapman et al., 2004, 2005). Further-
more, while exhibiting limited breadth, autologous neutralizing
responses in the first 6 months exert sufficient pressure on the
envelope to select for escape variants that become fixed in the
viral population (Bar et al., 2012; Moody et al., 2015). Any adap-
tive mutation in a given viral protein may lead to a functional
change. NAbs in particular can block HIV-1 receptor engage-
ment (i.e., blocking the CD4-binding site) or can prevent recep-
tor-binding-induced structural changes required for cell fusion
(exemplified by MPER-binding Abs) (Burton and Mascola,
2015). Thus, escape from NAbs may impact on these receptor-
driven rearrangements and, by extension, the route of cellular
entry as we saw for the 6-month viruses.
In keeping with the above, Envs from chronic viruses have
been shown to be less sensitive to CD4bs NAbs and to exhibit
differences in CCR5 engagement compared to Envs from TF vi-
ruses (Wilen et al., 2011). Whether IFITM sensitivity is a general
feature of NAb escape or specific to only certain epitopes and
whether these immune pressures select for additional compen-
satory changes require further study. It has been demonstrated
that TF viruses have 1.5-fold more virion-associated Env than
chronic viral isolates (Parrish et al., 2013). Whether this is a
reflection of increased virion incorporation or trimer stability is
not clear. Since IFITM sensitivity is modulated by CD4 engage-
ment, it is possible that Env density is a contributing factor to
IFITM resistance. However, previous studies of fusion kinetics
between TF and chronic envelopes have not found a significant
difference (Wilen et al., 2011). Furthermore, while not analyzed
here, we cannot exclude the possibility that Env escape muta-
tions in response to CD8+ T cell pressure in the same patients
(Liu et al., 2013) could not have also had a structural impact
that led to IFITM sensitivity.
TF viruses entering a naive host do so in the absence of
pre-existing adaptive immunity, but they must avoid innate re-
sponses to allow sufficient time to establish a systemic infection.
Thus, efficient cell entry into activated mucosal CD4+ T cells is
an absolute requirement for the virus. We suggest that viruses
that successfully transmit are those that can fuse efficiently at
the cell surface of cells expressing high CD4 levels. This would
endow such viruses with a relative resistance against IFN-
induced factors such as IFITMs, and it would particularly facili-
tate cell-to-cell spread in the face of the robust IFN-1 response
that occurs during acute infection (Stacey et al., 2009). However,
these requirements change during chronic infection when the
virus has to escape from pressures by the adaptive immune
system.
Amino acid changes in Env that allow escape from such adap-
tive responses may impact envelope function in such a way that
viral entry routes and, thus, restriction by IFITMs may change. It
is interesting to note that for three TF/6-month pairs used here,
NAb escape mutations were associated with a reduced ability
to replicate in CD4 T cells (Bar et al., 2012). Since activated
CD4 T cells express at least some IFITMs, it may well be that
fitness costs incurred by immune escape mutations reflect the
associated loss of effectively counteracting antiviral restriction.
In the case of the TF/6-month pairs tested here, IFITM restric-
tion in primary CD4+ T cells correlates with the IFN sensitivity
of the chronic virus. This would argue that, after the establish-
ment of chronic infection, the selective pressure of factors
such as IFITMs is no longer sufficient to impact viral replication
or, more likely, the counter-selection by adaptive immune re-
sponses is so strong that the effects of IFN-1-induced factors
like IFITMs on viral replication become tolerable.
Interestingly, there is evidence that IFN resistance increases
again during the late stages of HIV-1 infection (Fenton-May
et al., 2013). Understanding whether this inversely correlates
with the strength of the adaptive immune response will be partic-
ularly interesting. We therefore propose that IFITM restriction
and its inverse relationship with adaptive immune escape might
be a paradigm for demonstrating that a given ISG that inhibits
HIV-1 in vitro is likely to be of relevance in vivo.
Our data indicate that IFITMs represent major effectors of the
innate immune response to HIV-1 in vivo. Because of their
(C) U87/CD4/CCR5 IFITM-expressing cells were infected with TF viruses and their matched chronic pairs at anMOI of 0.5 in the presence of 0, 10, or 100 ng/mL of
CD4-blocking antibody SK3 for 6 hr. Then 48 hr post-infection, virus production wasmeasured by infection of HeLa-TZMbl indicator cells (**p < 0.01; *p < 0.05; ns,
p > 0.05, unpaired two-tailed t test).
All error bars represent ± SEM (n = 3). See also Figure S4.
10 Cell Host & Microbe 20, 1–14, October 12, 2016
Please cite this article in press as: Foster et al., Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction, Cell Host & Microbe (2016),
http://dx.doi.org/10.1016/j.chom.2016.08.006
(legend on next page)
Cell Host & Microbe 20, 1–14, October 12, 2016 11
Please cite this article in press as: Foster et al., Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction, Cell Host & Microbe (2016),
http://dx.doi.org/10.1016/j.chom.2016.08.006
sequence similarity, we were unable to find potent shRNAs that
could selectively knockdown endogenous IFITMs individually
in primary cells. However, the patterns of restriction observed
in ectopically expressing cell lines would suggest that the endo-
somal IFITMs 2 and 3 are the most contributing to the IFN sensi-
tivity of chronic viruses. The rs12252-C polymorphism in IFITM3
is predicted to result in a variant lacking the tyrosine-based
endocytic signal. This potentially would lead to surface expres-
sion of IFITM3 (Everitt et al., 2012). Recently this polymorphism
was associated with faster disease HIV-1 progression in China
(Zhang et al., 2015). Interestingly, there was no enhanced sus-
ceptibility to infection between different Ifitm3 genotypes. This
observation is entirely consistent with our data that both TF
and 6-month viruses are resistant to surface IFITM3. We predict
that the viruses that escape Env-directed adaptive immune re-
sponses in subjects carrying the rs12215-C polymorphism will
be less susceptible to host innate restriction, enhancing their
replication and therefore disease progression.
EXPERIMENTAL PROCEDURES
Plasmids and Reagents
Full details of HIV-1 molecular clones, HIV-1 Env plasmids, and IFITM expres-
sion constructs are described in the Supplemental Experimental Procedures.
Human IFITM1, IFITM2, and IFITM3 were cloned into pLHCX retroviral vector
(Clontech Laboratories). Mutants IFITM2-Y19F and IFITM3-Y20F were gener-
ated by site-directed mutagenesis using the parental pLHCX IFITM1, 2, or 3
constructs as templates. IFITM1, IFITM2, IFITM3, and Y19F or Y20F mutants
thereof were all HA tagged by PCR-based mutagenesis, again using the
parental pLHCX-IFITM1, 2, or 3 as templates.
Cell Culture
The 293T-, HeLa-TZMbl-, and U87-based cell lines were cultured, transfected,
or infected as described in the Supplemental Experimental Procedures. Hu-
man primary CD4+ T cells were isolated from peripheral blood mononuclear
cells (PBMCs) of healthy human donors and cultured and infected as outlined
in the Supplemental Experimental Procedures.
Virus and HIV-1 Env Pseudotyped Viral Vector Production
To generate virus and vector stocks, 293T cells were transfected with 10 mg
HIV-1 molecular clones plasmid or three-plasmid mix of pCSGW (GFP-encod-
ing vector genome), pCRV1-HIV-1 GagPol packaging vector, and pSVIII or
pCRV1 plasmids encoding various HIV-1 envelope glycoproteins. Super-
natants were harvested and filtered 48 hr post-transfection and titers were
calculated by standard methods. Full details are given in the Supplemental
Experimental Procedures.
shRNA Lentiviral Knockdown and CRISPR Knockout of IFITM
Expression
Silencing of IFITM expression was mediated either by lentiviral shRNA knock-
down in primary human CD4+ T cells or CRISPR knockout in U87 CD4+ CCR5+
cells, as outlined in the Supplemental Experimental Procedures.
Infections
U87/CD4/CXCR4+ or U87/CD4/CCR5 cells stably expressing IFITMs 1, 2,
or 3 or mutants thereof were infected with the indicated HIV-1 molecular
clone at an MOI of 0.05. Media were replaced 8 hr post-infection, and
culture supernatants were harvested every 24 hr post-infection for a total
of 120 hr. Infectious viral release was determined by infecting HeLa-
TZMbl indicator cells and 48 hr post-infection assaying for virus release
by measuring chemiluminescent b-galactosidase activity, using the Tropix
Galacto-Star system (Applied Biosystems) according to the manufacturer’s
instructions. For one-round virus release assays, cells were infected with
the indicated HIV-1 molecular clone at an MOI of 0.5. Viral production
was measured for supernatants harvested at 48 hr post-infection on
HeLa-TZMbl indicator cells, as above. For env-pseudotyped viral vector
entry assays, the same cells were infected with a fixed dose of HIV-1 viral
vectors at an MOI of 0.2 for 48–72 hr prior to analysis for GFP expression by
flow cytometry.
Activated CD4+ T cells, transduced with the appropriate shRNA lentiviral
vectors, were infected at an MOI of 0.1; then 8–12 hr post-infection, media
were replaced. Supernatants were harvested every 72, 120, and 168 hr
post-infection, and virus particle production was assessed on HeLa-TZMbl
cells as described previously.
CD4 Competition Assays
U87-MG CD4+ CCR5+ cells were infected at an MOI of 0.5 with the indicated
HIV-1 molecular clone/anti-human CD4 (SK3 clone, BioLegend) antibody
mix. Anti-human CD4 antibody was used at concentrations of 100, 10, and
0 ng/mL. Then 48 hr post-infection, supernatants were harvested and used
to infect HeLa-TZMbl cells, assaying for any dose-dependent reduction in
virus release as detailed in the Supplemental Experimental Procedures.
Ethics Statement
Ethical approval to use blood from healthy donors was granted by King’s
College London Infectious Disease BioBank Local Research Ethics Com-
mittee (under the authority of the Southampton and South West Hampshire
Research Ethics Committee—approval REC09/H0504/39), approval number
SN-1/6/7/9.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2016.08.006.
Figure 6. IFITM2 and IFITM3, in Particular, Contribute to the Inhibition of HIV-1 Replication in Primary CD4+ T Cells
(A) HIV-1 vectors pseudotyped with TF and 6-month envelope variants were used to challenge U87/CD4/CCR5 cells that had been pretreated overnight with
1,000 U/mL universal IFN-1. Infected cells were analyzed by flow cytometry 48 hr later (*p < 0.05; unpaired; unpaired two-tailed t test).
(B) U87/CD4/CCR5 cells were transduced with IFITM-specific or control lentiCRISPR-p2A-GFP vectors sufficiently to achieve 80%–98%GFP+. The efficiency of
CRISPR knockout of IFITM expression, in the absence or presence of IFN-1 (1,000 U/mL), was determined by western blotting. HSP90 served as a loading
control.
(C) Cells from (B) were challenged with CH077 at an MOI of 0.05 in the presence of absence of 1,000 U/mL IFN-1, and cumulative replication at 96 hr was
determined as previously described.
(D) Primary CD4+ T cells were transduced with shRNAs targeting IFITM1, 2, or 3 or a control shRNA and cultured for 72 hr. Transduced cells were cultured with or
without 500 U/mL IFN-1 for 24 hr before determining the efficiency of IFITM knockdown by western blot analysis. HSP90 served as a loading control.
(E) CD4+ T cells, expressing control or IFITM-specific shRNAs, were infected with the indicated TF and chronic matched-pair viruses at an MOI of 0.05. A time
course of replication, in the presence or absence of 500 U/mL universal IFN-1, was assayed with supernatants harvested every 24 hr for a total of 5 days. In-
fectious virus was determined by infection of HeLa-TZMbl indicator cells. Data shown are representative of the replication values at 96 hr, and IFITM shRNA
knockdown data are expressed relative to the virus-specific TF control sample. Data shown are representative of three independent donors and independent
experiments.
Statistical significance between indicated pairs was determined using an unpaired two-tailed t test (**p < 0.01; *p < 0.05; ns, p > 0.05). All error bars represent ±
SEM (n = 3). See also Figure S5.
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